Sector Expert: Thomas Yip

FBR & Co.



Recent Quotes

"CPXX's CombiPlex could improve the therapeutic index of MTA combinations."

— Thomas Yip, FBR Capital Markets (9/24/15)
more >

"CPXX guides to a Q1/16 data readout from the Phase 3 Vyxeos trial."

— Thomas Yip, MLV & Co (8/12/15)
more >

"OMER's Omidria is one step closer to European Union approval."

— Thomas Yip, MLV & Co (5/26/15)
more >



Due to permission requirements, not all quotes are shown.